van der Laan Liselot, Karimi Karim, Rooney Kathleen, Lauffer Peter, McConkey Haley, Caro Pilar, Relator Raissa, Levy Michael A, Bhai Pratibha, Mignot Cyril, Keren Boris, Briuglia Silvana, Sobering Andrew K, Li Dong, Vissers Lisenka E L M, Dingemans Alexander J M, Valenzuela Irene, Verberne Eline A, Misra-Isrie Mala, Zwijnenburg Petra J G, Waisfisz Quinten, Alders Mariëlle, Sailer Sebastian, Schaaf Christian P, Mannens Marcel M A M, Sadikovic Bekim, van Haelst Mieke M, Henneman Peter
Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
Genet Med. 2024 Mar;26(3):101050. doi: 10.1016/j.gim.2023.101050. Epub 2023 Dec 18.
Hao-Fountain syndrome (HAFOUS) is a neurodevelopmental disorder caused by pathogenic variants in USP7. HAFOUS is characterized by developmental delay, intellectual disability, speech delay, behavioral abnormalities, autism spectrum disorder, seizures, hypogonadism, and mild dysmorphic features. We investigated the phenotype of 18 participants with HAFOUS and performed DNA methylation (DNAm) analysis, aiming to generate a diagnostic biomarker. Furthermore, we performed comparative analysis with known episignatures to gain more insight into the molecular pathophysiology of HAFOUS.
We assessed genomic DNAm profiles of 18 individuals with pathogenic variants and variants of uncertain significance (VUS) in USP7 to map and validate a specific episignature. The comparison between the USP7 cohort and 56 rare genetic disorders with earlier reported DNAm episignatures was performed with statistical and functional correlation.
We mapped a sensitive and specific DNAm episignature for pathogenic variants in USP7 and utilized this to reclassify the VUS. Comparative epigenomic analysis showed evidence of HAFOUS similarity to a number of other rare genetic episignature disorders.
We discovered a sensitive and specific DNAm episignature as a robust diagnostic biomarker for HAFOUS that enables VUS reclassification in USP7. We also expand the phenotypic spectrum of 9 new and 5 previously reported individuals with HAFOUS.
郝-方丹综合征(HAFOUS)是一种由USP7基因致病性变异引起的神经发育障碍。HAFOUS的特征包括发育迟缓、智力残疾、语言发育迟缓、行为异常、自闭症谱系障碍、癫痫、性腺功能减退和轻度畸形特征。我们对18名HAFOUS患者的表型进行了研究,并进行了DNA甲基化(DNAm)分析,旨在生成一种诊断生物标志物。此外,我们与已知的表观遗传特征进行了比较分析,以更深入地了解HAFOUS的分子病理生理学。
我们评估了18名USP7基因存在致病性变异和意义未明变异(VUS)的个体的基因组DNAm图谱,以绘制和验证一种特定的表观遗传特征。通过统计和功能相关性分析,将USP7队列与56种已报道过DNAm表观遗传特征的罕见遗传疾病进行了比较。
我们绘制了USP7基因致病性变异的一种敏感且特异的DNAm表观遗传特征,并利用它对VUS进行了重新分类。比较表观基因组分析显示,HAFOUS与其他一些罕见遗传表观遗传特征疾病存在相似性。
我们发现了一种敏感且特异的DNAm表观遗传特征,作为HAFOUS的一种可靠诊断生物标志物,可实现USP7中VUS的重新分类。我们还扩展了9名新的和5名先前报道的HAFOUS患者的表型谱。